Stay updated with breaking news from Patrickj Crutcher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biotech Stock News Bite - Avalo Therapeutics, Inc. (NASDAQ: AVTX) Makes NASDAQ Top Gainers List on News it acquired Phase 2-ready anti-IL-1β mAb
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc.Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to
(0) BESTHESDA, Maryland and CASTRES, France, April 8, 2021 /PRNewswire/ -- The US biopharmaceutical company ValenzaBio and the French pharmaceutical group Pierre Fabre announced today the signing of a license agreement of a preclinical insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody, for the treatment of Thyroid Eye Disease (TED), an endocrine disease with unmet medical need. ValenzaBio received from Pierre Fabre the worldwide and exclusive rights to develop and commercialize, outside of oncology, the anti-IGF-1R antibody, discovered by Pierre Fabre at its Center of immunol...